US 10,864,245 B2 · Activation and expansion of NKG2C+ NK cells

Abstract

The invention relates to an isolated peptide for use as a medicament, wherein said peptide has 9 to 30 amino acids and comprises or consists of an amino acid sequence according to SEQ ID NO 1 (VMAPRTLXL), wherein X is an amino acid with a hydrophobic side chain (A, I, L, F, V, P, G), preferably V, L, I or F. The invention further relates to the peptide of the invention for use as a medicament to expand and/or activate NKG2C+ natural killer (NK) cells. The invention further relates to the peptide of the invention for use in the treatment and/or prevention of a medical condition associated with pathogenic cells expressing HLA-E and a peptide comprising an amino acid sequence according to SEQ ID NO 1 or 2. Additionally, the invention relates to a genetically modified virus encoding a peptide comprising or consisting of a polypeptide of the invention for use as a medicament to expand and/or activate NKG2C+ natural killer (NK) cells.

Claims13

Dependent claims

A method of treating a subject having or being at risk of developing a medical condition associated with pathogenic cells expressing HLA-E and a peptide comprising an amino acid sequence according to SEQ ID NO:

1 or SEQ ID NO:
2, the method comprising administering to said subject an effective amount of an isolated peptide of 9 to 30 amino acids comprising an amino acid sequence according to SEQ ID NO:2 (VMAPRTLFL), wherein the method expands and/or activates NKG2C+ natural killer (NK) cells, wherein the medical condition is a cancer associated with expression of HLA-G and HLA-E, wherein the cancer is identified by:
a) providing a sample comprising cancer cells from the subject, and
b) determining expression of HLA-G and HLA-E in said sample.

1 more element

Dependencies are inferred from the claim text.

Activation and expansion of NKG2C+ NK cells

Life of this patent

Activation and expansion of NKG2C+ NK cells

Life of this patent

Abstract

Claims13